Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Elicio Therapeutics (ELTX) Profit After Tax (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Profit After Tax readings, the most recent being -$8.9 million for Q4 2023.

  • On a quarterly basis, Profit After Tax fell 34.55% to -$8.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$35.2 million, a 24.77% decrease, with the full-year FY2025 number at -$39.6 million, up 23.75% from a year prior.
  • Profit After Tax hit -$8.9 million in Q4 2023 for Elicio Therapeutics, up from -$10.7 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $14.9 million in Q4 2021 to a low of -$36.7 million in Q1 2021.
  • Median Profit After Tax over the past 4 years was -$9.8 million (2023), compared with a mean of -$12.4 million.
  • The widest YoY moves for Profit After Tax: up 151.57% in 2021, down 177.47% in 2021.
  • Elicio Therapeutics' Profit After Tax stood at -$28.9 million in 2020, then surged by 151.57% to $14.9 million in 2021, then tumbled by 144.67% to -$6.7 million in 2022, then tumbled by 34.55% to -$8.9 million in 2023.
  • The last three reported values for Profit After Tax were -$8.9 million (Q4 2023), -$10.7 million (Q3 2023), and -$7.6 million (Q2 2023) per Business Quant data.